Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 2;12:770390. doi: 10.3389/fimmu.2021.770390

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Datsi and Sorg

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Dendritic cell vaccination (DCV) and targeting the immunosuppression in the tumor microenvironment (TME). Combining DCV with therapies targeting the three immunosuppressive cell populations of the TME—regulatory T cells (Treg), tumor-associated macrophages (TAM), or myeloid-derived suppressor cells (MDSC)—might improve efficacy. Potential target strategies include restoring the responsiveness of the dysfunctional T cells (pink), applying effector T cells by adoptive transfer (purple), depleting immunosuppressive cells, and modulating the inflammatory conditions in the TME (green) and blocking the mechanisms of immunosuppression (red).